An Introduction to Retina/Vitreous
Retinal diseases are a leading cause of vision loss and blindness, but advances in imaging and treatment have improved patient outcomes over recent years. The introduction of OCT-A has had a big impact on the diagnosis and management of conditions such as diabetic macular oedema (DMO) and diabetic retinopathy. The treatment landscape of these conditions was revolutionized following the introduction of anti-VEGF therapies, and research into longer-lasting, multi-targeted treatments is currently underway.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
The Safety of Medical Devices Used During Intraocular Surgery
US Ophthalmic Review. 2021;13(2):73–5 DOI: https://doi.org/10.17925/USOR.2020.13.2.73
Since 2013, a series of acute ocular toxicity events have occurred, causing hundreds of cases of irreversible blindness. This has prompted the questioning of measures adopted by health regulatory bodies to approve the commercialization of certain products.1 The greatest problem is the use of perfluorocarbon liquids; however, cases of toxicity have occurred with other intraocular substances […]
Antibiotic Stewardship in Ophthalmic Clinical Practice
Since the introduction of antibiotics, bacterial resistance has continued to pose an ongoing problem across all infectious diseases,1 and ocular infection pathogens are no exception. Antibiotic resistance in ophthalmology has become an important global health issue. A total of 4.5 million cataract surgeries are performed each year.2 These carry a risk of postoperative infection, particularly endophthalmitis, a severe sight-threatening inflammation of the eye.3,4 As a result, a number of common antibiotics are prescribed to prevent infections.5 Since up to 97% of ophthalmologists use post-operative antibiotics, this is equivalent to 61 million days per year of antibiotic exposure.6 Antibiotics are also used in the treatment of common ophthalmic infections such as acute infective conjunctivitis, which is one of the most common issues encountered in primary care and constitutes a significant healthcare burden.7 Antimicrobial resistance, which develops naturally through gene mutations, has been identified as a major healthcare threat worldwide, largely due to overuse and misuse of antibiotics. The presence of antibiotic resistance among ocular pathogens is a major concern, as it complicates the choice of antibiotic and may lead to treatment failure.8 The need for responsible use of antibiotics is increasingly recognised, and in recent years, the concept of antimicrobial stewardship has developed. Antibiotic stewardship has been defined in a consensus statement from the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, and the Pediatric Infectious Diseases Society as ‘coordinated interventions designed to improve and measure the appropriate use of [antibiotic] agents by promoting the selection of the optimal [antibiotic] drug regimen including dosing, duration of therapy, and route of administration’.9 Santen have recently launched the Re-SOLVE Antibiotic Resistance initiative, which aims to promote antibiotic stewardship by recommending a set of actions which encourage the sustainable and effective use of antibiotics, including selection of an antibiotic therapy.10 In an expert interview, Mr Ali Mearza describes the aims of the RE-SOLVE initiative. Q. Could you tell us a little about the aims of the Re-SOLVE antibiotic initiative? The campaign launched in October 2020 and was dedicated to the importance and benefits of sustainable antibiotic use in ophthalmology.10 The Re-SOLVE campaign aims to rapidly and responsibly raise awareness of the threat of antibiotic resistance in ophthalmology; catalyse an environment of urgent action and antibiotic stewardship in the ophthalmology community; and promote awareness of, and access to, medical education opportunities and networks of helpful experts. Q. What practical advice would you give to ophthalmologists in terms of the use of prophylactic antibiotics during and after cataract surgery, and infectious complications such as endophthalmitis? During cataract surgery, there is now good evidence to support the use of povidone-iodine in the conjunctival sac prior to the commencement of surgery, followed by intracameral antibiotic (either cefuroxime or moxifloxacin) at the end of surgery.11,12 This has been showed to lower the incidence of endophthalmitis significantly. Following surgery, a short course of antibiotic x4/day for a week, makes more sense rather than a prolonged 4-week course as is the case still in many centres. Q. What is the importance of selecting a therapy with short duration to minimise antibiotic use in everyday practice? Short-term therapy (1 week) may be enough post-operatively as an additional measure above using povidone-iodine and intracameral antibiotics during cataract surgery. Additionally, no tapering – these two factors could positively impact the lowering antibiotic exposure and slow down the development of antibiotic resistance. Q. How else can ophthalmologists select antibiotic therapies that will minimise antibiotic use in everyday practice? It is important that, where possible, the most appropriate antibiotic is selected and used for the shortest duration of time possible. Most departments work closely with their microbiology colleagues to develop guidelines on the most appropriate use of antibiotics and these should be reviewed yearly in line with changes in antibiotic resistance. Antibiotics should not be used where not indicated, and ongoing training and education will help instil the message of appropriate use for the next generation of ophthalmologists. References World Health Organisation. Antimicrobial resistance. Available at: www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (accessed 4 November 2020). Eurostat. Cataract surgery: how countries compare. Available at: https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20190108-1 (accessed 4 November 2020). Gower EW, Lindsley K, Tulenko SE, et al. Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery. Cochrane Database Syst Rev. 2017;2:Cd006364. Garg P, Roy A, Sharma S. Endophthalmitis after cataract surgery: epidemiology, risk factors, and evidence on protection. Curr Opin Ophthalmol. 2017;28:67–72. ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery: Data, Dilemmas and Conclusions 2013. Available at: www.escrs.org/downloads/Endophthalmitis-Guidelines.pdf (accessed 4 November 2020). Haripriya A. Antibiotic prophylaxis in cataract surgery – An evidence-based approach. Indian J Ophthalmol. 2017;65:1390–5. Ryder EC, Benson S. Conjunctivitis. [Updated 2020 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available at: Available from: www.ncbi.nlm.nih.gov/books/NBK541034/ (accessed 4 November 2020). Asbell PA, DeCory HH. Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. PLoS One. 2018;13:e0205814. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of america and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62:e51–77. Santen joins forces with ophthalmologists in the fight against antibiotic resistance. Available at: www.santen.eu/our-vision/emea-news/santen-joins-forces-ophthalmologists-fight-against-antibiotic-resistance (accessed 4 November 2020). Ahmed Y, Scott IU, Pathengay A, et al. Povidone-iodine for endophthalmitis prophylaxis. Am J Ophthalmol. 2014;157:503–4. Titiyal JS, Kaur M. Role of intracameral antibiotics in endophthalmitis prophylaxis following-cataract surgery. Indian J Ophthalmol. 2020;68:688–91. Author profile: Mr Ali Mearza is Director and founding partner of Ophthalmic Consultants of London, UK. He is also the Clinical Director of Ophthalmology at London’s Imperial College Healthcare NHS Trust, London, the UK’s first Academic Health Sciences Centre. His specialist interests are in laser and lens vision correction techniques, cataract surgery and corneal transplantation. He has a keen interest in clinical research and has over 30 peer-reviewed publications to his name and is an invited journal reviewer. His publications range from case reports, book chapters, clinical reviews and studies looking at new techniques and technologies. Many of his surgical techniques are featured on his YouTube channel which has over 300 000 views to date. He’s also featured in the media with television appearances on the Discovery Channel as well in mainstream media publications. Disclosures: Ali Mearza has nothing to disclose in relation to this expert interview. Support: Commissioned, edited and supported by Touch Medical Media, who commissioned the interview in liaison with Santen. Writing assistance was provided by Katrina Mountfort from Touch Medical Media. Published: 27 January 2021
J Fernando Arevalo, AAO 2020 – Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms
It was a pleasure to catch up with our valued Editorial Board member, J Fernando Arevalo (Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA), who gave his insights on his topic at the retina subspecialty day at AAO 2020, intravitreal anti-VEGF injections for exudative retinal arterial macroaneurysms. Questions Could you give […]
Tommaso Rossi, EURETINA 2020 – Novel Instrument for Internal Limiting Membrane
We were delighted to catch up with Prof. Tommaso Rossi, who talked us through his presentation at EURETINA 2020 concerning a novel instrument for internal limiting membrane, amniotic and retinal flap manipulation. Questions What is the rationale for the use of amniotic membrane grafts in vitreoretinal surgery, and in what ophthalmic indications are they used? […]
Peter Stalmans, EURETINA 2020 – End-stage Retinitis Pigmentosa Patients Implanted with 3D–neural Interface Retinal Prosthesis
Prof. Peter Stalmans (University Hospitals, Leuven, Belgium) talked us through his presentation at EURETINA on first reported clinical results from end-stage retinitis pigmentosa patients implanted with an innovative 3D neural interface retinal prosthesis. Questions Could you give us an overview of advances in retinal prosthesis approaches in the treatment of advanced retinitis pigmentosa […]
Optical Lens Tinting—A Review of its Functional Mechanism, Efficacy, and Applications
US Ophthalmic Review. 2019;12(2):85–7
Optical lens filtration therapy began with FL-41 lenses that were developed in the late 1980s and first reported in 1991 by Wilkins and Wilkinson.1 They were originally designed to improve workplace productivity by reducing eye strain and headaches induced by fluorescent lighting. They were designed to allow only 10% light filtration from 400–550 nm with a […]
Verteporfin Photodynamic Therapy for the Treatment of Choroidal Conditions—An Overview
US Ophthalmic Review, 2019;12(2):69–78
Photodynamic therapy (PDT) is a technique involving the use of a photosensitizing agent that, when activated by light of a specific wavelength, causes localized and selective tissue damage.1,2 Initially developed to treat tumor cells using tumor-localizing photosensitizing agents (e.g., Photofrin®, Pinnacle Biologics, Chicago, IL USA),1 ophthalmic PDT was developed in the 1990s to treat conditions such as […]
Post-cataract Cystoid Macular Oedema Prevention – Update 2019
European Ophthalmic Review. 2019;13(1): 37–43 DOI: https://doi.org/10.17925/EOR.2019.13.1.37
Various options for the prevention of pseudophakic cystoid macular oedema (PCMO) have been offered. Nonsteroidal anti-inflammatory drugs (NSAIDs) seem to be beneficial in preventing postoperative inflammation; however, there is lack of evidence for long-term benefit after cataract surgery. What is more, topical NSAID preparations are difficult to compare, as studies differ in inclusion criteria, patient […]
Jost Jonas, EURETINA 2019 – Myopia: Epidemiology, Histology & Clinics
It was fantastic to meet up with Jost Jonas (Ruprecht-Karls University) to discuss the Keynote Lecture ‘Myopia: Epidemiology, Histology & Clinics’ he presented at this year’s meeting. Support: No funding was received in the production of this video. Disclosures: Jost Jonas has nothing to disclose in relation to this video.
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!